Answers are grounded in this paper and cite their sources.
Background: A study was undertaken to record exacerbations and health resource use in patients with COPD during 6 months of treatment with tiotropium, salmeterol, or matching placebos. Methods: Patients with COPD were enrolled in two 6-month randomised, placebo controlled, double blind, double dummy studies of tiotropium 18 g once daily via HandiHaler or salmeterol 50 g twice daily via a metered dose inhaler. The two trials were combined for analysis of heath outcomes consisting of exacerbations, health resource use, dyspnoea (assessed by the transitional dyspnoea index, TDI), health related quality of life (assessed by St George's Respiratory Questionnaire, SGRQ), and spirometry.
No takes yet. Share an insight, caveat, or question.
Vito Brusasco (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: